Switzerland and the pharmaceutical industry have been travelling a successful path together for decades. An economic policy that provides attractive framework conditions has favoured the impressive development of the research-based pharmaceutical industry. At the same time, the pharmaceutical industry is a pillar of the economy, contributing to Switzerland’s prosperity to an above-average degree. The pharmaceutical industry will continue to need optimum framework conditions in the future, and Switzerland needs successful companies. Political stability, legal certainty, open export markets, the availability of a qualified workforce and an attractive fiscal landscape are all factors that play a major role in this symbiosis.
3 questions to Thorsten Hein - Member of theInterpharma Board and Country Division Head Pharmaceuticals Bayer Switzerland
3 questions to Graham Dorey - Member Interpharma Board and General Manager Switzerland, Biogen
3 questions to Max Pahlow - Member Interpharma Board and Managing Director, Janssen Switzerland
Facts & Figures
Interpharma, the association of Switzerland’s research-based pharmaceutical industry, was founded in Basel in 1933.
Interpharma informs the public about issues that are important to the research-based pharmaceutical industry in Switzerland, including the pharma market in Switzerland, healthcare and biomedical research.
Information on our key figures and activities in the financial year 2022
More about the tasks and overriding aims of Interpharma
Latest information and media contacts for media representatives